TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the
13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc. (NASDAQ:TGTX) with a price target of $15, based on the report released on February 27. The firm’s price target is the lowest among Wall Street analysts, based on 8 analysts covering the stock, and it reflects a 49% downside from the current levels.
The rating came after TG Therapeutics, Inc. (NASDAQ:TGTX) reported its fourth-quarter financial results on February 26. Net income for the quarter reached $23 million, bringing full-year net income to $447.2 million. The company generated total global revenue of $616 million for 2025, including $594 million from U.S. BRIUMVI net product sales and $12.8 million from Neuraxpharm.
Operating expenses for the year reached about $328 million. For 2026, operating expenses are projected at $350 million, plus an additional $100 million for subcutaneous manufacturing and start-up activities.
TG Therapeutics, Inc. (NASDAQ:TGTX) Chief Commercial Officer, Adam Waldman, commented on the outlook:
Turning to the first quarter … We expect U.S. revenue to grow sequentially over Q4 levels to approximately $185 million to $190 million.
Copyright:
nimon / 123RF Stock Photo
TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company. The company focuses on the development, commercialization, and acquisition of novel treatments for B-cell-mediated diseases across the United States and globally. It is based in Morrisville, North Carolina.
While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and Goldman Sachs Value Stocks: 10 Stocks to Buy.
Disclosure: None.
Follow Insider Monkey on Google News.
